Business
Medicure Announces AGM Results and Appointment of New Director
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in ...
About this update from Medicure Inc.
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announces the voting results from its Annual General Meeting of shareholders (the "Meeting") held today, including the appointment of Kerrie Hayes to the board of directors of the Company. A total of 5,237,796 common shares (representing 50.19% of the votes attached to all outstanding common shares of the Company as at the record date) were voted in person or by proxy at the Meeting. All resolutions presented to shareholders were approved. More specifically, shareholders voted in favour of: Dr. Albert Friesen, CEO of the Company, commented "On behalf of Medicure, I would like to thank shareholders for their participation and continued support. We are pleased to welcome Kerrie Hayes to the Board as an independent director and look forward to her contributions, particular in the areas of applied research, business development and intellectual property management." Kerrie Hayes is currently the Director, Research Contracts at the University of Manitoba. In this role she provides institutional oversight for complex research agreements and international partnership contracting. Previously, Ms. Hayes was Director of Business Development at Medicure and Intellectual Property Manager at a life sciences incubator. She holds an M.Sc. in Biosciences from the University of Winnipeg. The Company also announces that Peter Quick has stepped down as a director of Medicure as of the time of the Meeting. "Personally, and on behalf of the Board, I want to acknowledge and express my sincere thanks for Peter's many contributions to Medicure over the past twenty years and wish him the very best moving forward," stated Dr. Friesen. About Medicure Inc.Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, ...